Expand ATNM Menu
ATNM MENU

ATNM Latest Press Releases

-- December 12, 2025 --

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 PRNewswire 8:45 AM

-- December 11, 2025 --

Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia AB Digital Inc 3:05 PM

-- December 9, 2025 --

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer AB Digital Inc 3:07 PM

-- December 8, 2025 --

Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa AB Digital Inc 2:44 PM

-- December 1, 2025 --

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium PRNewswire 8:45 AM

-- November 4, 2025 --

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications PRNewswire 7:30 AM

-- November 3, 2025 --

Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference PRNewswire 8:30 AM

-- October 27, 2025 --

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PRNewswire 7:00 AM

-- October 24, 2025 --

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat PRNewswire 8:30 AM

-- October 13, 2025 --

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PRNewswire 12:11 PM
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat PRNewswire 8:30 AM
Market Data Delayed 15 Minutes